On Friday, Bristol-Myers Squibb Co (NYSE: BMY) opened lower -3.70% from the last session, before settling in for the closing price of $55.97. Price fluctuations for BMY have ranged from $39.35 to $61.10 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 18.97%. Company’s average yearly earnings per share was noted 491.93% at the time writing. With a float of $2.03 billion, this company’s outstanding shares have now reached $2.03 billion.
Let’s determine the extent of company efficiency that accounts for 34100 employees. In terms of profitability, gross margin is 66.66%, operating margin of 17.86%, and the pretax margin is -17.35%.
Bristol-Myers Squibb Co (BMY) Insider Activity
A key investor’s attitude towards the stock of the Drug Manufacturers – General industry is another important factor to consider. The insider ownership of Bristol-Myers Squibb Co is 0.12%, while institutional ownership is 79.65%. The most recent insider transaction that took place on Nov 04 ’24, was worth 38,930. In this transaction SVP and Controller of this company sold 700 shares at a rate of $55.62, taking the stock ownership to the 11,760 shares. Before that another transaction happened on Nov 01 ’24, when Company’s EVP,Chief Med.Offr.,Drug Dev. bought 1,830 for $54.67, making the entire transaction worth $100,055. This insider now owns 62,109 shares in total.
Bristol-Myers Squibb Co (BMY) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.7 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 491.93% per share during the next fiscal year.
Bristol-Myers Squibb Co (NYSE: BMY) Trading Performance Indicators
Check out the current performance indicators for Bristol-Myers Squibb Co (BMY). In the past quarter, the stock posted a quick ratio of 1.15. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.26. Likewise, its price to free cash flow for the trailing twelve months is 7.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.43, a number that is poised to hit 1.53 in the next quarter and is forecasted to reach 6.16 in one year’s time.
Technical Analysis of Bristol-Myers Squibb Co (BMY)
Looking closely at Bristol-Myers Squibb Co (NYSE: BMY), its last 5-days average volume was 11.21 million, which is a jump from its year-to-date volume of 10.95 million. As of the previous 9 days, the stock’s Stochastic %D was 18.09%. Additionally, its Average True Range was 1.43.
During the past 100 days, Bristol-Myers Squibb Co’s (BMY) raw stochastic average was set at 39.95%, which indicates a significant increase from 3.46% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 27.19% in the past 14 days, which was lower than the 29.16% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $57.36, while its 200-day Moving Average is $50.41. However, in the short run, Bristol-Myers Squibb Co’s stock first resistance to watch stands at $55.40. Second resistance stands at $56.89. The third major resistance level sits at $57.76. If the price goes on to break the first support level at $53.03, it is likely to go to the next support level at $52.16. Should the price break the second support level, the third support level stands at $50.67.
Bristol-Myers Squibb Co (NYSE: BMY) Key Stats
There are currently 2,029,312K shares outstanding in the company with a market cap of 109.38 billion. Presently, the company’s annual sales total 48,300 M according to its annual income of -8,948 M. Last quarter, the company’s sales amounted to 12,342 M and its income totaled 72,000 K.
